A detailed history of Jennison Associates LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Jennison Associates LLC holds 4,699,332 shares of VRTX stock, worth $2.36 Billion. This represents 1.42% of its overall portfolio holdings.

Number of Shares
4,699,332
Previous 4,782,374 1.74%
Holding current value
$2.36 Billion
Previous $2 Billion 10.18%
% of portfolio
1.42%
Previous 1.34%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024

SELL
$392.81 - $485.53 $32.6 Million - $40.3 Million
-83,042 Reduced 1.74%
4,699,332 $2.2 Billion
Q1 2024

May 02, 2024

BUY
$407.69 - $446.08 $341 Million - $374 Million
837,461 Added 21.23%
4,782,374 $2 Billion
Q4 2023

Feb 01, 2024

BUY
$343.0 - $410.68 $50.5 Million - $60.5 Million
147,248 Added 3.88%
3,944,913 $1.61 Billion
Q3 2023

Oct 31, 2023

SELL
$338.18 - $362.46 $2.7 Million - $2.89 Million
-7,976 Reduced 0.21%
3,797,665 $1.32 Billion
Q2 2023

Aug 03, 2023

SELL
$314.42 - $351.91 $243 Million - $272 Million
-774,160 Reduced 16.9%
3,805,641 $1.34 Billion
Q1 2023

Apr 26, 2023

SELL
$283.23 - $323.1 $152 Million - $173 Million
-535,739 Reduced 10.47%
4,579,801 $1.44 Billion
Q4 2022

Feb 09, 2023

BUY
$285.76 - $321.48 $103 Million - $116 Million
359,719 Added 7.56%
5,115,540 $1.48 Billion
Q3 2022

Nov 01, 2022

BUY
$273.83 - $305.53 $817 Million - $911 Million
2,983,253 Added 168.3%
4,755,821 $1.38 Billion
Q2 2022

Aug 02, 2022

BUY
$234.96 - $292.55 $334 Million - $416 Million
1,422,478 Added 406.32%
1,772,568 $499 Million
Q1 2022

May 11, 2022

SELL
$221.42 - $260.97 $95.9 Million - $113 Million
-433,299 Reduced 55.31%
350,090 $91.4 Million
Q4 2021

Feb 08, 2022

SELL
$177.01 - $223.45 $8.14 Million - $10.3 Million
-45,970 Reduced 5.54%
783,389 $172 Million
Q3 2021

Nov 09, 2021

BUY
$181.39 - $202.99 $6.81 Million - $7.62 Million
37,531 Added 4.74%
829,359 $150 Million
Q2 2021

Aug 12, 2021

BUY
$187.49 - $221.1 $14.3 Million - $16.8 Million
76,039 Added 10.62%
791,828 $160 Million
Q1 2021

May 11, 2021

SELL
$207.02 - $241.31 $628 Million - $732 Million
-3,033,565 Reduced 80.91%
715,789 $154 Million
Q4 2020

Feb 05, 2021

BUY
$207.01 - $276.09 $29 Million - $38.7 Million
140,270 Added 3.89%
3,749,354 $886 Million
Q3 2020

Nov 04, 2020

SELL
$255.65 - $303.1 $207 Million - $245 Million
-809,397 Reduced 18.32%
3,609,084 $982 Million
Q2 2020

Aug 06, 2020

BUY
$225.48 - $295.8 $12.8 Million - $16.8 Million
56,726 Added 1.3%
4,418,481 $1.28 Billion
Q1 2020

May 06, 2020

BUY
$199.77 - $247.81 $158 Million - $196 Million
790,506 Added 22.14%
4,361,755 $1.04 Billion
Q4 2019

Feb 07, 2020

SELL
$166.71 - $223.91 $401 Million - $539 Million
-2,406,492 Reduced 40.26%
3,571,249 $782 Million
Q3 2019

Nov 08, 2019

SELL
$166.23 - $187.09 $61 Million - $68.6 Million
-366,718 Reduced 5.78%
5,977,741 $1.01 Billion
Q2 2019

Aug 06, 2019

SELL
$164.61 - $190.37 $75.1 Million - $86.8 Million
-455,977 Reduced 6.71%
6,344,459 $0
Q1 2019

May 10, 2019

SELL
$163.73 - $194.7 $23.1 Million - $27.5 Million
-141,185 Reduced 2.03%
6,800,436 $1.25 Billion
Q4 2018

Feb 06, 2019

BUY
$151.91 - $192.21 $112 Million - $142 Million
739,128 Added 11.92%
6,941,621 $1.15 Billion
Q3 2018

Nov 08, 2018

BUY
$167.73 - $192.74 $191 Million - $220 Million
1,139,486 Added 22.51%
6,202,493 $1.2 Billion
Q2 2018

Aug 02, 2018

SELL
$145.72 - $169.96 $250 Million - $291 Million
-1,712,321 Reduced 25.27%
5,063,007 $861 Million
Q1 2018

Apr 20, 2018

BUY
$151.6 - $177.13 $188 Million - $219 Million
1,237,421 Added 22.34%
6,775,328 $1.1 Billion
Q4 2017

Jan 25, 2018

SELL
$137.28 - $155.55 $65.9 Million - $74.6 Million
-479,859 Reduced 7.97%
5,537,907 $830 Million
Q3 2017

Nov 03, 2017

BUY
$148.13 - $162.24 $891 Million - $976 Million
6,017,766
6,017,766 $915 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Jennison Associates LLC Portfolio

Follow Jennison Associates LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jennison Associates LLC with notifications on news.